cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase

Naohisa Tamura, Hiroshi Itoh, Yoshihiro Ogawa, Osamu Nakagawa, Masaki Harada, Tae Hwa Chun, Shin Ichi Suga, Takaaki Yoshimasa, Kazuwa Nakao

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

The type I cGMP-dependent protein kinase (cGK) is one of the major pathways for the cGMP cascade and has been demonstrated to inhibit platelet aggregation, relax smooth muscle cells, and control cardiocyte contractility. There are two subtypes of the type I cGK, cGKIα and cGKIβ. The former is more sensitive to cGMP than the latter. In humans, cGKIβ cDNA was isolated, but the full structure and tissue-specific gene expression of cGKIα have not been determined. The significance of cGK in human cardiovascular diseases has not been investigated at the molecular level. In the present study, we isolated the full-length human cGKIα cDNA (-36 to +2177: the translation start site: +1) encoding the 671-amino acid protein. Nucleotides +267 to +2177 of the isolated cDNA were identical to the corresponding nucleotides of human cGKIβ cDNA. Southern blot analysis suggested that human cGKIα and cGKIβ are generated by alternative splicing of a single gene assigned to chromosome 10. By Northern blot analysis, we detected abundant human cGKIα mRNA (7.0 kb) in the aorta, heart, kidneys, and adrenals. In contrast, human cGKIβ mRNA (7.0 kb) was detected abundantly only in the uterus. In cultured vascular smooth muscle cells, the type I cGK mRNA concentration was reduced to 10% of the basal level by 4 x 10 -10 mol/L platelet-derived growth factor. Angiotensin II (10 -8 mol/L), transforming growth factor-β (4 x 10 -11 mol/L), and tumor necrosis factor-α (6 x 10 -6 mol/L) also exhibited an inhibitory effect on type I cGK gene expression. These findings suggest a pathophysiological implication of the type I cGK in cardiovascular diseases, including hypertension and atherosclerosis.

Original languageEnglish
Pages (from-to)552-557
Number of pages6
JournalHypertension
Volume27
Issue number3 II
Publication statusPublished - Mar 1 1996

Fingerprint

Cyclic GMP-Dependent Protein Kinase Type I
Organism Cloning
Complementary DNA
Gene Expression
Messenger RNA
Smooth Muscle Myocytes
Cardiovascular Diseases
Nucleotides
Cyclic GMP-Dependent Protein Kinases
Chromosomes, Human, Pair 10
Platelet-Derived Growth Factor
Alternative Splicing
Transforming Growth Factors
Southern Blotting
human PRKG1 protein
Platelet Aggregation
Vascular Smooth Muscle
Angiotensin II
Northern Blotting
Uterus

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Tamura, N., Itoh, H., Ogawa, Y., Nakagawa, O., Harada, M., Chun, T. H., ... Nakao, K. (1996). cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase. Hypertension, 27(3 II), 552-557.

cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase. / Tamura, Naohisa; Itoh, Hiroshi; Ogawa, Yoshihiro; Nakagawa, Osamu; Harada, Masaki; Chun, Tae Hwa; Suga, Shin Ichi; Yoshimasa, Takaaki; Nakao, Kazuwa.

In: Hypertension, Vol. 27, No. 3 II, 01.03.1996, p. 552-557.

Research output: Contribution to journalArticle

Tamura, N, Itoh, H, Ogawa, Y, Nakagawa, O, Harada, M, Chun, TH, Suga, SI, Yoshimasa, T & Nakao, K 1996, 'cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase', Hypertension, vol. 27, no. 3 II, pp. 552-557.
Tamura N, Itoh H, Ogawa Y, Nakagawa O, Harada M, Chun TH et al. cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase. Hypertension. 1996 Mar 1;27(3 II):552-557.
Tamura, Naohisa ; Itoh, Hiroshi ; Ogawa, Yoshihiro ; Nakagawa, Osamu ; Harada, Masaki ; Chun, Tae Hwa ; Suga, Shin Ichi ; Yoshimasa, Takaaki ; Nakao, Kazuwa. / cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase. In: Hypertension. 1996 ; Vol. 27, No. 3 II. pp. 552-557.
@article{f41a7d5082274ea287966768bc5078b4,
title = "cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase",
abstract = "The type I cGMP-dependent protein kinase (cGK) is one of the major pathways for the cGMP cascade and has been demonstrated to inhibit platelet aggregation, relax smooth muscle cells, and control cardiocyte contractility. There are two subtypes of the type I cGK, cGKIα and cGKIβ. The former is more sensitive to cGMP than the latter. In humans, cGKIβ cDNA was isolated, but the full structure and tissue-specific gene expression of cGKIα have not been determined. The significance of cGK in human cardiovascular diseases has not been investigated at the molecular level. In the present study, we isolated the full-length human cGKIα cDNA (-36 to +2177: the translation start site: +1) encoding the 671-amino acid protein. Nucleotides +267 to +2177 of the isolated cDNA were identical to the corresponding nucleotides of human cGKIβ cDNA. Southern blot analysis suggested that human cGKIα and cGKIβ are generated by alternative splicing of a single gene assigned to chromosome 10. By Northern blot analysis, we detected abundant human cGKIα mRNA (7.0 kb) in the aorta, heart, kidneys, and adrenals. In contrast, human cGKIβ mRNA (7.0 kb) was detected abundantly only in the uterus. In cultured vascular smooth muscle cells, the type I cGK mRNA concentration was reduced to 10{\%} of the basal level by 4 x 10 -10 mol/L platelet-derived growth factor. Angiotensin II (10 -8 mol/L), transforming growth factor-β (4 x 10 -11 mol/L), and tumor necrosis factor-α (6 x 10 -6 mol/L) also exhibited an inhibitory effect on type I cGK gene expression. These findings suggest a pathophysiological implication of the type I cGK in cardiovascular diseases, including hypertension and atherosclerosis.",
author = "Naohisa Tamura and Hiroshi Itoh and Yoshihiro Ogawa and Osamu Nakagawa and Masaki Harada and Chun, {Tae Hwa} and Suga, {Shin Ichi} and Takaaki Yoshimasa and Kazuwa Nakao",
year = "1996",
month = "3",
day = "1",
language = "English",
volume = "27",
pages = "552--557",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "3 II",

}

TY - JOUR

T1 - cDNA cloning and gene expression of human type Iα cGMP-dependent protein kinase

AU - Tamura, Naohisa

AU - Itoh, Hiroshi

AU - Ogawa, Yoshihiro

AU - Nakagawa, Osamu

AU - Harada, Masaki

AU - Chun, Tae Hwa

AU - Suga, Shin Ichi

AU - Yoshimasa, Takaaki

AU - Nakao, Kazuwa

PY - 1996/3/1

Y1 - 1996/3/1

N2 - The type I cGMP-dependent protein kinase (cGK) is one of the major pathways for the cGMP cascade and has been demonstrated to inhibit platelet aggregation, relax smooth muscle cells, and control cardiocyte contractility. There are two subtypes of the type I cGK, cGKIα and cGKIβ. The former is more sensitive to cGMP than the latter. In humans, cGKIβ cDNA was isolated, but the full structure and tissue-specific gene expression of cGKIα have not been determined. The significance of cGK in human cardiovascular diseases has not been investigated at the molecular level. In the present study, we isolated the full-length human cGKIα cDNA (-36 to +2177: the translation start site: +1) encoding the 671-amino acid protein. Nucleotides +267 to +2177 of the isolated cDNA were identical to the corresponding nucleotides of human cGKIβ cDNA. Southern blot analysis suggested that human cGKIα and cGKIβ are generated by alternative splicing of a single gene assigned to chromosome 10. By Northern blot analysis, we detected abundant human cGKIα mRNA (7.0 kb) in the aorta, heart, kidneys, and adrenals. In contrast, human cGKIβ mRNA (7.0 kb) was detected abundantly only in the uterus. In cultured vascular smooth muscle cells, the type I cGK mRNA concentration was reduced to 10% of the basal level by 4 x 10 -10 mol/L platelet-derived growth factor. Angiotensin II (10 -8 mol/L), transforming growth factor-β (4 x 10 -11 mol/L), and tumor necrosis factor-α (6 x 10 -6 mol/L) also exhibited an inhibitory effect on type I cGK gene expression. These findings suggest a pathophysiological implication of the type I cGK in cardiovascular diseases, including hypertension and atherosclerosis.

AB - The type I cGMP-dependent protein kinase (cGK) is one of the major pathways for the cGMP cascade and has been demonstrated to inhibit platelet aggregation, relax smooth muscle cells, and control cardiocyte contractility. There are two subtypes of the type I cGK, cGKIα and cGKIβ. The former is more sensitive to cGMP than the latter. In humans, cGKIβ cDNA was isolated, but the full structure and tissue-specific gene expression of cGKIα have not been determined. The significance of cGK in human cardiovascular diseases has not been investigated at the molecular level. In the present study, we isolated the full-length human cGKIα cDNA (-36 to +2177: the translation start site: +1) encoding the 671-amino acid protein. Nucleotides +267 to +2177 of the isolated cDNA were identical to the corresponding nucleotides of human cGKIβ cDNA. Southern blot analysis suggested that human cGKIα and cGKIβ are generated by alternative splicing of a single gene assigned to chromosome 10. By Northern blot analysis, we detected abundant human cGKIα mRNA (7.0 kb) in the aorta, heart, kidneys, and adrenals. In contrast, human cGKIβ mRNA (7.0 kb) was detected abundantly only in the uterus. In cultured vascular smooth muscle cells, the type I cGK mRNA concentration was reduced to 10% of the basal level by 4 x 10 -10 mol/L platelet-derived growth factor. Angiotensin II (10 -8 mol/L), transforming growth factor-β (4 x 10 -11 mol/L), and tumor necrosis factor-α (6 x 10 -6 mol/L) also exhibited an inhibitory effect on type I cGK gene expression. These findings suggest a pathophysiological implication of the type I cGK in cardiovascular diseases, including hypertension and atherosclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0029915360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029915360&partnerID=8YFLogxK

M3 - Article

VL - 27

SP - 552

EP - 557

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 3 II

ER -